Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Akebia Therapeutics Inc shares valued at $60,150 were sold by Malabre Richard C on Jun 09 ’25. At $4.01 per share, Malabre Richard C sold 15,000 shares. The insider’s holdings dropped to 266,914 shares worth approximately $0.97 million following the completion of this transaction.
Also, Malabre Richard C sold 13,334 shares, netting a total of over 47,069 in proceeds. Following the sale of shares at $3.53 each, the insider now holds 266,914 shares.
Before that, Butler John P. had sold 46,409 shares from its account. In a trade valued at $84,928, the CEO and President traded Akebia Therapeutics Inc shares for $1.83 each. Upon closing the transaction, the insider’s holdings decreased to 46,409 shares, worth approximately $9.34 million.
Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of April 01, 2025, Jefferies has initiated its “Buy” rating for AKBA.
Analyzing AKBA Stock Performance
On last trading session,, Akebia Therapeutics Inc [NASDAQ: AKBA] rose 2.24% to $3.65. The stock’s lowest price that day was $3.49, but it reached a high of $3.7 in the same session. During the last five days, there has been a drop of approximately -1.08%. Over the course of the year, Akebia Therapeutics Inc shares have jumped approximately 92.11%.
Support And Resistance Levels for Akebia Therapeutics Inc (AKBA)
RSI (Relative Strength Index) is 66.12 on the 14-day chart, showing neutral technical sentiment.
Is Akebia Therapeutics Inc subject to short interest?
Stocks of Akebia Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 2.28 million shares to 20.05 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 17.77 million shares. A jump of 11.39% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.2 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.2.
Which companies own the most shares of Akebia Therapeutics Inc (AKBA)?
In terms of Akebia Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6.5 in the next 12 months, up nearly 82.07% from the previous closing price of $3.57. Analysts anticipate Akebia Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 6. In spite of this, 4 analysts ranked Akebia Therapeutics Inc stock as Buy at the end of 2025. On August 28, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and upgraded coverage with a $3.75.
